AdvaMed tells Congress Medicare is too slow
Members of AdvaMed told the House Commerce Committee’s subcommittee on health and environment last month that new medical technologies are reaching patients too slowly because of delays in the Health Care Financing Administration’s coding,
Members of AdvaMed told the House Commerce Committees subcommittee on health and environment last month that new medical technologies are reaching patients too slowly because of delays in the Health Care Financing Administrations coding, coverage, and payment systems.
Patients can wait four-and-a-half years or more to be diagnosed by or treated with new medical technologies because of Medicare procedures, said David Fleming, group senior vice president of Genzyme Corp. and chair of the AdvaMed Board Committee on Payment and Health Care Delivery, at the hearing.
AdvaMed has been actively working to pass the Medicare Patient Access to Technology Act. The bill would eliminate reimbursement and coding delays, the association believes.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
